Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group
SJ Van Deventer, CO Elson, RN Fedorak - Gastroenterology, 1997 - Elsevier
SJ Van Deventer, CO Elson, RN Fedorak
Gastroenterology, 1997•ElsevierBACKGROUND & AIMS: Interleukin 10 (IL-10) is a cytokine with immunosuppressive and
anti-inflammatory activities. Gene-targeted IL-10-deficient mice develop a chronic intestinal
inflammatory disease that is reminiscent of Crohn's disease. The present double-blind
randomized multicenter trial was designed to evaluate the safety, tolerance, and
pharmacokinetics of IL-10 in Crohn's disease. METHODS: Forty-six patients with active
steroid-resistant Crohn's disease were treated with one of five doses of recombinant human …
anti-inflammatory activities. Gene-targeted IL-10-deficient mice develop a chronic intestinal
inflammatory disease that is reminiscent of Crohn's disease. The present double-blind
randomized multicenter trial was designed to evaluate the safety, tolerance, and
pharmacokinetics of IL-10 in Crohn's disease. METHODS: Forty-six patients with active
steroid-resistant Crohn's disease were treated with one of five doses of recombinant human …
BACKGROUND & AIMS
Interleukin 10 (IL-10) is a cytokine with immunosuppressive and anti-inflammatory activities. Gene-targeted IL-10- deficient mice develop a chronic intestinal inflammatory disease that is reminiscent of Crohn's disease. The present double-blind randomized multicenter trial was designed to evaluate the safety, tolerance, and pharmacokinetics of IL-10 in Crohn's disease.
METHODS
Forty-six patients with active steroid-resistant Crohn's disease were treated with one of five doses of recombinant human IL-10 (0.5, 1, 5, 10, or 25 micrograms/kg) or placebo administered once daily by intravenous bolus injection over 7 consecutive days.
RESULTS
Treatment was safe and well tolerated, and no evidence for IL-10 accumulation was observed at the end of the treatment period. At the end of the study, Crohn's disease activity scores were 179 in IL-10-treated patients and 226 in patients receiving placebo. The proportion of patients that experienced a complete remission at any time in the 3-week follow-up period was 50% in the IL-10 group and 23% in placebo-treated patients.
CONCLUSIONS
These results indicate that IL-10 administered as a daily bolus injection over 1 week is safe and well tolerated and may be clinically efficacious. (Gastroenterology 1997 Aug;113(2):383-9)
Elsevier